collection
MENU ▼
Read by QxMD icon Read
search

ICS and PNA risk in COPD

shared collection
6 papers 25 to 100 followers
By Jason Mann No BS pulmonary critical care fellow
https://www.readbyqxmd.com/read/25537556/inhaled-corticosteroids-in-copd-the-clinical-evidence
#1
REVIEW
Pierre Ernst, Nathalie Saad, Samy Suissa
In this article, we focus on the scientific evidence from randomised trials supporting treatment with inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease (COPD), including treatment with combinations of long-acting β-agonist (LABA) bronchodilators and ICS. Our emphasis is on the methodological strengths and limitations that guide the conclusions that may be drawn. The evidence of benefit of ICS and, therefore, of the LABA/ICS combinations in COPD is limited by major methodological problems...
February 2015: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/22781123/chronic-respiratory-disease-inhaled-corticosteroids-and-risk-of-non-tuberculous-mycobacteriosis
#2
Claire Andréjak, Rikke Nielsen, Vibeke Ø Thomsen, Pierre Duhaut, Henrik Toft Sørensen, Reimar Wernich Thomsen
BACKGROUND: Chronic respiratory disease and inhaled corticosteroid (ICS) therapy for chronic obstructive pulmonary disease (COPD) increase the risk of pneumonia. Few data are available on the association of these risk factors with non-tuberculous mycobacterial (NTM) pulmonary disease. METHODS: This study examined chronic respiratory diseases and ICS use as risk factors in a population-based case-control study encompassing all adults in Denmark with microbiologically confirmed NTM pulmonary disease between 1997 and 2008...
March 2013: Thorax
https://www.readbyqxmd.com/read/25323619/the-wisdom-of-inhaled-corticosteroids-in-copd
#3
EDITORIAL
David M G Halpin, Jennifer K Quint
No abstract text is available yet for this article.
December 2014: Thorax
https://www.readbyqxmd.com/read/25196117/withdrawal-of-inhaled-glucocorticoids-and-exacerbations-of-copd
#4
RANDOMIZED CONTROLLED TRIAL
Helgo Magnussen, Bernd Disse, Roberto Rodriguez-Roisin, Anne Kirsten, Henrik Watz, Kay Tetzlaff, Lesley Towse, Helen Finnigan, Ronald Dahl, Marc Decramer, Pascal Chanez, Emiel F M Wouters, Peter M A Calverley
BACKGROUND: Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored. METHODS: In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period...
October 2, 2014: New England Journal of Medicine
https://www.readbyqxmd.com/read/21975759/inhaled-corticosteroids-versus-long-acting-beta-2-agonists-for-chronic-obstructive-pulmonary-disease
#5
REVIEW
Sally Spencer, David J Evans, Charlotta Karner, Christopher J Cates
BACKGROUND: Long-acting beta(2)-agonists and inhaled corticosteroids can be used as maintenance therapy by patients with moderate to severe chronic obstructive pulmonary disease. These interventions are often taken together in a combination inhaler. However, the relative added value of the two individual components is unclear. OBJECTIVES: To determine the relative effects of inhaled corticosteroids (ICS) compared to long-acting beta(2)-agonists (LABA) on clinical outcomes in patients with stable chronic obstructive pulmonary disease...
2011: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/24130228/inhaled-corticosteroids-in-copd-and-the-risk-of-serious-pneumonia
#6
COMPARATIVE STUDY
Samy Suissa, Valérie Patenaude, Francesco Lapi, Pierre Ernst
BACKGROUND: Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of pneumonia varies for different inhaled agents, particularly fluticasone and budesonide, and increases with the dose and long-term duration of use. METHODS: We formed a new-user cohort of patients with COPD treated during 1990-2005. Subjects were identified using the Quebec health insurance databases and followed through 2007 or until a serious pneumonia event, defined as a first hospitalisation for or death from pneumonia...
November 2013: Thorax
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"